Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volarivir + imerimevir (± ribavirin) in chronic HCV genotype 1
CTR20180159Phase 2Completed
- Sponsor
- Dongguan Dongyangguang Taijing Pharmaceutical Research and Development
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of furaprevir, yimitasvir in hepatitis C virus infection, sponsored by Dongguan Dongyangguang Taijing Pharmaceutical Research and Development. Started Apr 2018; status: completed.
02
Drugs
furapreviryimitasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on CTR20180159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180159.